Tema Etfs LLC Acquires New Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Tema Etfs LLC acquired a new position in Immunocore Holdings plc (NASDAQ:IMCR - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 11,194 shares of the company's stock, valued at approximately $330,000.

A number of other hedge funds also recently bought and sold shares of IMCR. Groupama Asset Managment purchased a new stake in Immunocore in the 4th quarter worth approximately $17,700,000. Deep Track Capital LP purchased a new stake in shares of Immunocore in the fourth quarter worth $15,322,000. Point72 Asset Management L.P. purchased a new stake in shares of Immunocore in the fourth quarter worth $11,897,000. T. Rowe Price Investment Management Inc. raised its position in shares of Immunocore by 3.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock valued at $197,657,000 after purchasing an additional 200,373 shares during the period. Finally, Primecap Management Co. CA lifted its stake in shares of Immunocore by 8.0% during the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock valued at $78,722,000 after buying an additional 196,530 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Trading Down 1.4%

Shares of IMCR stock traded down $0.45 on Thursday, reaching $31.21. 100,819 shares of the company's stock were exchanged, compared to its average volume of 417,722. The company's fifty day simple moving average is $28.93 and its 200 day simple moving average is $30.05. The stock has a market capitalization of $1.56 billion, a PE ratio of -32.85 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. Immunocore Holdings plc has a 52 week low of $23.15 and a 52 week high of $51.50.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. The firm had revenue of $125.13 million during the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business's revenue was up 33.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.49) earnings per share. As a group, analysts forecast that Immunocore Holdings plc will post -0.94 EPS for the current year.

Insider Activity at Immunocore

In other news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the business's stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the purchase, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 10.40% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on IMCR shares. JPMorgan Chase & Co. cut their price target on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research note on Monday, April 14th. HC Wainwright reissued a "buy" rating and set a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. Needham & Company LLC reissued a "buy" rating and issued a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. Morgan Stanley reaffirmed an "equal weight" rating and set a $35.00 price objective on shares of Immunocore in a report on Friday, March 7th. Finally, Oppenheimer boosted their target price on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $58.13.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.